Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results

INTRODUCTION: Psoriasis is a debilitating, chronic inflammatory systemic disease affecting around 2% of the South American population. Biological therapies offer the possibility of long-term therapy with improved safety and efficacy. METHODS: We conducted a multicentre, open-label, single-arm, Phase...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Stengel, Fernando M, Petri, Valeria, Campbell, Gladys AM, Dorantes, Gladys Leon, López, Magdalina, Galimberti, Ricardo L, Valdez, Raúl P, de Arruda, Lucia F, Guerra, Mario Amaya, Chouela, Edgardo N, Licu, Daiana
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Publishing Inc 2009
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2805872/
https://ncbi.nlm.nih.gov/pubmed/20098510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1753-5174.2009.00024.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak